← Back to Clinical Trials
Recruiting NCT04914611

NCT04914611 Real World Assessment of People Living With Chronic Hepatitis B in Australia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04914611
Status Recruiting
Phase
Sponsor Kirby Institute
Condition Hepatitis B
Study Type OBSERVATIONAL
Enrollment 10,000 participants
Start Date 2022-02-17
Primary Completion 2030-07-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
No intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 10,000 participants in total. It began in 2022-02-17 with a primary completion date of 2030-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The REACH-B study establishes an observational cohort study of people living with chronic hepatitis B from a national network, including a diverse range of services, to characterise and monitor hepatitis B linkage to care and treatment requirements amongst this population.

Eligibility Criteria

Inclusion Criteria: 1. All individuals diagnosed with chronic hepatitis B in the participating study sites are eligible to be included (both newly diagnosed cases and those diagnosed in the past). 2. 16 years of age or older. 3. Attended the health service for HBV care within the prior 12 months from study commencement (retrospective recruitment) OR Attending the health service for HBV care from study commencement (prospective recruitment) Exclusion Criteria: 1\. Nil

Contact & Investigator

Central Contact

Jessica Carter

✉ jcarter@kirby.unsw.edu.au

📞 +61290654212

Principal Investigator

Gail Matthews, PhD MBBS

PRINCIPAL INVESTIGATOR

Kirby Insitute, UNSW

Frequently Asked Questions

Who can join the NCT04914611 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatitis B. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04914611 currently recruiting?

Yes, NCT04914611 is actively recruiting participants. Contact the research team at jcarter@kirby.unsw.edu.au for enrollment information.

Where is the NCT04914611 trial being conducted?

This trial is being conducted at Sydney, Australia, Sydney, Australia, Sydney, Australia, Sydney, Australia and 11 additional locations.

Who is sponsoring the NCT04914611 clinical trial?

NCT04914611 is sponsored by Kirby Institute. The principal investigator is Gail Matthews, PhD MBBS at Kirby Insitute, UNSW. The trial plans to enroll 10,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology